Alexandre Zanghellini Bio: Cyrus Biotechnology CEO, Age, Career, Protein Design Innovation, Family & 2026 Recent Works

Alexandre Zanghellini is a distinguished French-American scientist, entrepreneur, and the co-founder and CEO of Cyrus Biotechnology, a leading company specializing in AI-driven protein design. As a pioneer in the field of computational biology, his biography reflects the transformation of drug discovery from traditional trial-and-error methods to precise, software-led engineering. By 2026, Zanghellini has become a central figure in the synthetic biology revolution, bridging the gap between academic research and commercial therapeutic breakthroughs.

Quick Facts

Early Life & Education

Childhood

Alexandre Zanghellini was born and raised in France during a period of rapid technological advancement in Europe. Growing up in an environment that valued rigorous academic discipline, Zanghellini showed an early affinity for the natural sciences and mathematics. His childhood was marked by a curiosity about how the molecular world functioned, often spending his free time reading about chemistry and the emerging field of computer science.

School Years

During his secondary education in France, Zanghellini excelled in the “Classes Préparatoires,” an intensive two-year program designed to prepare the highest-achieving students for entry into France’s elite Grandes Écoles. This period was foundational for his analytical skills, instilling a “first-principles” approach to problem-solving that would later define his career as a CEO.

University & Training

Zanghellini’s academic journey took a significant turn when he moved to the United States for advanced graduate studies. He enrolled at the University of Washington (UW) in Seattle, a global hub for protein research. It was here that he joined the world-renowned “Baker Lab,” led by Dr. David Baker.

At UW, Zanghellini focused on the development of the Rosetta software suite—a collective project aimed at predicting and designing the 3D structures of proteins. His doctoral work was groundbreaking, as he successfully designed the first de novo enzymes, proving that scientists could create biological catalysts from scratch rather than just modifying existing ones. This achievement solidified his status as a visionary in the field of synthetic biology.

Career Journey

The Baker Lab and the Genesis of Rosetta

Alexandre Zanghellini’s career began in the trenches of computational biochemistry. During his time as a researcher at the University of Washington, he was part of the core team that built Rosetta, the most powerful software package for protein folding and design. While most academic research remains confined to journals, Zanghellini saw a massive commercial opportunity. He realized that if pharmaceutical companies could use Rosetta, they could reduce the time and cost of drug development by years.

Founding Cyrus Biotechnology (2014–2020)

In 2014, Zanghellini co-founded Cyrus Biotechnology alongside other veterans of the Baker Lab. The company was named after Cyrus Levinthal, a famous molecular biologist. The mission was clear: take the complex, academic Rosetta software and turn it into a user-friendly, cloud-based platform for the biotech industry.

As CEO, Zanghellini successfully navigated the “Valley of Death” that many startups face. He secured initial funding from prominent venture capital firms like Orbimed, Trinity Ventures, and AME Cloud Ventures. Under his leadership, Cyrus transitioned from a software provider to a therapeutics company, using its own tools to discover new drugs for autoimmune diseases and oncology.

Global Expansion and AI Integration (2021–2025)

By the early 2020s, the rise of Generative AI changed the landscape of protein design. Zanghellini led Cyrus through a strategic evolution, integrating Large Language Models (LLMs) and diffusion models—similar to the technology behind DALL-E but for molecular structures—into their workflow. This era saw Cyrus forming massive partnerships with “Big Pharma” giants like Selecta Biosciences and Janssen, positioning Zanghellini as a bridge between Silicon Valley tech and East Coast pharma.

2026 Recent Works and Current Activity

As of 2026, Alexandre Zanghellini is overseeing the clinical trial phases for several Cyrus-designed proteins. His recent activity includes:

• Generative Proteomics: Launching a new proprietary platform that allows for “one-click” protein optimization, significantly reducing off-target effects in biologics.
• Sustainability Initiatives: Leading a consortium to use protein design for carbon capture and plastic degradation, expanding Cyrus’s reach beyond human health.
• Strategic Acquisitions: Acquiring several smaller AI-bio startups to consolidate Cyrus as the leading “full-stack” protein engineering house in the Pacific Northwest.

Career Milestones & Bibliography

Net Worth & Earnings

Alexandre Zanghellini’s net worth in 2026 is estimated to be between $15 million and $25 million. While his salary as CEO is substantial, the bulk of his wealth is tied to his equity in Cyrus Biotechnology. As the company continues to hit clinical milestones and increase its valuation through AI integration, his “on-paper” net worth has grown significantly.

His income streams include:

1. Executive Compensation: Annual salary and performance bonuses.
2. Equity/Stock Options: Significant holdings in Cyrus, which has seen multiple rounds of high-value venture funding.
3. Consultancy & Board Seats: Serving as an advisor to emerging tech and bio-ventures.
4. Investments: Diversified holdings in the broader Seattle real estate market and tech startups.

Personal Life

Family Background

Zanghellini maintains a relatively private life regarding his family. It is known that his parents were supportive of his move to the United States, encouraging his pursuit of higher education. His multicultural background (French roots and American professional life) allows him to navigate international business deals with a unique cultural fluency.

Marriage & Spouse

Alexandre is married and lives with his family in the Greater Seattle area. His spouse is reportedly supportive of his high-intensity career, though she remains out of the public spotlight to maintain the family’s privacy.

Hobbies, Interests & Lifestyle

Despite his busy schedule, Zanghellini is an advocate for a healthy work-life balance. He is an avid hiker, taking advantage of the Pacific Northwest’s mountainous terrain. He is also a fan of fine arts and classical music, often attending performances in Seattle. His lifestyle is described as “intellectually active,” often engaging in debates regarding the ethics of AI and genetic engineering.

Awards & Achievements

• Innovation in Biology Award | 2025 | International Synthetic Biology Society
• Top 40 Under 40 in Biotech | 2019 | BioSpace
• Ph.D. Excellence Award | 2008 | University of Washington
• Pioneer in Computational Chemistry | 2023 | Global Science Forum

Physical Statistics

• Height: 5’10” (178 cm)
• Weight: 165 lbs (75 kg)
• Build: Lean/Athletic
• Eye Color: Brown
• Hair Color: Dark Brown
• Distinguishing Features: Often seen wearing professional-casual attire, characterized by a sharp, academic yet approachable demeanor.

Quotes

“The goal of Cyrus is to make the design of a life-saving protein as predictable and efficient as designing a microchip.” — TechCrunch Interview, 2024

“We are moving from an era of discovering drugs to an era of engineering them.” — Keynote at Bio-IT World, 2025

Favorites

• Food: French Cuisine (specifically Coq au Vin)
• Book: The Structure of Scientific Revolutions by Thomas Kuhn
• Travel Destination: The French Alps
• Sport: Soccer (Football)
• City: Seattle, WA

Interesting Facts

• He was one of the first people in the world to successfully create a “designer enzyme” that does not exist in nature.
• Zanghellini is fluent in both French and English, often speaking at international conferences in both languages.
• He is a strong proponent of “Open Science,” despite leading a commercial enterprise.
• Cyrus Biotechnology, his company, is named after a scientist who questioned why proteins fold the way they do (Levinthal’s Paradox).
• He moved to Seattle specifically because of the University of Washington’s reputation in molecular science.
• His work has been cited thousands of times in academic literature, even before he became a CEO.
• He believes that AI will eventually solve the problem of “undruggable” diseases.
• He is known for a “flat” management style, often eating lunch with junior engineers and scientists.

Did You Know?

• Did you know Alexandre Zanghellini helped write the original code for Rosetta, the software that now powers the world’s leading protein design labs?
• Did you know he transitioned from a pure scientist to a CEO by teaching himself venture capital and business law during his early startup days?
• Did you know his company, Cyrus, uses cloud computing to run millions of biological simulations every single day?

Social Media

• LinkedIn: Alexandre Zanghellini
• X (Twitter): @AlexZanghellini (Official Company/Personal hybrid)
• Company Website: CyrusBio.com

Frequently Asked Questions

Q1: How old is Alexandre Zanghellini?
A: As of 2026, Alexandre Zanghellini is approximately 46 years old, based on his academic timeline.

Q2: What is Cyrus Biotechnology?
A: Cyrus Biotechnology is a software and drug discovery company co-founded by Zanghellini that uses AI and the Rosetta platform to design new proteins for medical use.

Q3: Where did Alexandre Zanghellini go to school?
A: He completed his undergraduate studies in France and earned his Ph.D. from the University of Washington in Seattle.

Q4: Is Alexandre Zanghellini still the CEO of Cyrus?
A: Yes, as of 2026, he remains the CEO and continues to lead the company’s strategic direction in AI-driven therapeutics.

CONCLUSION

Alexandre Zanghellini’s biography is a testament to the power of interdisciplinary expertise. By combining deep molecular biology with advanced computational techniques, he has fundamentally changed how the world approaches drug discovery. As we move further into 2026, his work at Cyrus Biotechnology continues to push the boundaries of what is possible in medicine, promising a future where diseases are treated with custom-engineered proteins. His legacy is one of innovation, transition, and a relentless pursuit of scientific excellence.

Sources: University of Washington Alumni Records, Cyrus Biotechnology Corporate Press Kit, Forbes Biotech Archives, Nature Journal Publications.